pharmaphorum

NOVEMBER 14, 2022

IQVIA examined the top 100 companies by global sales revenue (IQVIA MIDAS) and extracted data on commitments and progress (Figure 1). About the author. Here is what was found: Less than half of top 100 companies have reported time-bound commitments.

Pharmaceutical Companies 105

Pharmaceutical Companies Pharmaceutical Companies 105

pharmaphorum

MARCH 17, 2022

The team from Heinrich Heine University in Dusseldorf and healthcare data science company IQVIA identified the possible correlation after analysing health records from 8.8 ” He acknowledged that the authors themselves note their work is preliminary, and that larger datasets are needed.

Hospitals 102

Hospitals 102

pharmaphorum

FEBRUARY 28, 2022

The analysis by IQVIA and pharma company Chiesi looked at the per patient, per year (PPPY) direct, indirect and mortality-related costs associated with 24 rare diseases, and compared them to 24 chronic ailments like diabetes, heart disease, arthritis and cancers.

Documentation 98

Documentation Hospitals 98

pharmaphorum

OCTOBER 18, 2022

IQVIA conducted a thorough analysis of 12 global DCT studies across three therapeutic areas and seven indications to compare DCTs’ value to key stakeholders with traditional trials. About the author. Patricia Salter, Head of Global DCT Operations, IQVIA.

Communication 95

Communication Vaccines 95

pharmaphorum

OCTOBER 7, 2022

IQVIA has the long term market data, from World Reviews back to 1978, to investigate, and analysed nearly 30 years of launches into leading therapy classes, from multiple eras in the development of the pharmaceutical industry. About the author. Is this true? The launches into these therapy areas happened from 1995 onwards.

FDA 85

FDA 85

pharmaphorum

MAY 17, 2021

Commercial model reshaping (41% of respondents) and readiness of customer facing teams (34% of respondents) were key challenges identified by life science companies in an IQVIA survey in October 2020. Analysis of Net Promoter Score in IQVIA’s ChannelDynamics data presents some interesting findings. About the authors.

Communication 57

Communication 57

pharmaphorum

DECEMBER 13, 2022

If BYOD is used to capture copyrighted or validated questionnaires, it is advisable to engage with the copyright holders and authors early to identify any particular conditions for use if questionnaires are implemented in a BYOD solution. About the author. Prior to joining IQVIA in 2018, J.C.

Data Entry 59

Data Entry HIPAA Insurance Communication 59

European Pharmaceutical Review

DECEMBER 19, 2022

Although the joint-statement is said to be necessary owing to the “uncertainty among stakeholders on the use of biosimilars in clinical practice”, a 2021 report by IQVIA found that the volume of biosimilar prescribing across the European Economic Area generated €5.7 About the authors. EMA Biosimilars Q&A. Lausuntopalvelu.fi.

52

52

pharmaphorum

APRIL 1, 2022

Matthias is an internationally experienced professional at a senior level in the healthcare industry with a focus to create value for public and private provider organisations, commissioner, life science companies, governments and authorities. Jim McArdle , commercial director, Interface Clinical Services, IQVIA.

97

97

pharmaphorum

SEPTEMBER 14, 2022

As will be discussed at the 2022 DPharm annual conference in Boston, IQVIA, a global clinical research organization, surveyed more than 6,400 participants across the U.S. About the author. Mark Brown, Vice President, Global Patient and Site Solutions, IQVIA.

Vaccines 96

Vaccines Medical Records Documentation Communication 96

European Pharmaceutical Review

SEPTEMBER 2, 2022

An RMP is submitted as part of the dossier of all new drug applications and is evaluated by regulatory authorities before authorisation is given. Such as plan may also be requested by regulatory authorities for authorised products without one in place should concerns arise about a risk affecting the benefit-risk balance. References.

Adverse Reactions 76

Adverse Reactions Documentation Medical Schools Packaging 76

pharmaphorum

JUNE 30, 2022

At DIA, we presented findings from a 2021 global survey of patients and study investigators conducted by IQVIA, which showed that both groups are interested in decentralized trials (DCTs). About the Author. It’s vital we know what’s necessary to interest patients and sites in trial participation.

Communication 64

Communication 64

pharmaphorum

NOVEMBER 24, 2020

IQVIA’s Sarah Rickwood explores how pharma can help healthcare systems address treatment backlogs caused by the COVID-19 pandemic. In an August 2020 paper in the Lancet Oncology, the authors noted that referrals via the 2-week-wait urgent pathway for suspected cancer in England were reported to have decreased by 84%.

Pharmaceutical Companies 74

Pharmaceutical Companies Pharmaceutical Companies Vaccines Chemotherapy 74

Omnicell

JANUARY 10, 2023

Streamline PA approval and get meds to patients quickly Omnicell Specialty Pharmacy Services helped Bausch Health improve XIFAXAN adherence in many ways, starting with the prior authorization (PA) process. PA authorization and adherence monitoring are just two of the many turnkey solutions provided by Omnicell Specialty Pharmacy Services.

Specialty Pharmacies 52

Specialty Pharmacies Omnicell Hospitals Medication Delivery 52

pharmaphorum

JUNE 1, 2022

About the authors. As chief medical officer, Dr. James Kyle Bryan is responsible for strategic global medical and scientific leadership for IQVIA Biotech, leading the Medical, Safety, Feasibility, Oncology Strategy and Global Strategic Delivery teams. Dr. Keefer received a BA in Biology from the University of Virginia and MD and Ph.D.

Hospitals 59

Hospitals 59

pharmaphorum

NOVEMBER 20, 2020

Prior to joining Prescient, he led teams and projects at Kantar Health, AlphaImpactRx (now part of IQVIA) and Psyma International across the development timeline, including competitive intelligence, licensing and BD assessments, market landscapes, tracking studies, pricing and market access studies, and strategic workshops.

Medical Schools 55

Medical Schools 55

pharmaphorum

JANUARY 25, 2023

About the author Susan Hill joined IQVIA in 2018 as part of the acquisition of AHM and is responsible for the customer engagement and commercial compliance technology offerings.

Communication 98

Communication 98

pharmaphorum

APRIL 16, 2021

IQVIA’s Sarah Rickwood reviews the launch of innovative medicines in 2020 and outlines three key pillars of activity for companies to focus on and address in 2021. Availability in a commercial distribution channel, as measured by appearance in IQVIA audit data. About the author.

Pharmaceutical Companies 84

Pharmaceutical Companies Pharmaceutical Companies Documentation Vaccines 84

pharmaphorum

JANUARY 27, 2023

About the author Marie E. Lamont is the global head of RWE Data Strategy, Access & Enablement at IQVIA and general manager at Inteliquet, a patient-matching clinical trial software company.

Medical Records 109

Medical Records Patient Care Hospitals 109

Omnicell

MARCH 27, 2023

According to recent data from IQVIA , 340B program sales grew 15.9% Disclaimer The views and opinions expressed in this blog are those of the authors. Assumptions made in the analysis do not reflect the position of any entity other than the author(s). in 2021, reaching $93.6 billion versus total pharmaceutical sales of $668.3

Omnicell 52

Omnicell Specialty Pharmacies Community Pharmacies Documentation 52

Omnicell

JANUARY 10, 2023

For example, during a main stage session outlining industry trends, issues, and outlook, Doug Long, vice president of industry relations at IQVIA, showed specialty pharmacy growth outpacing traditional pharmacy growth, accounting for more than 50 percent of non-discounted drug spending.

Specialty Pharmacies 52

Specialty Pharmacies Omnicell Hospitals Insurance 52

pharmaphorum

FEBRUARY 21, 2022

Cynthia Verst spoke to MedCity about how IQVIA no longer relies solely on academic medical sites to hold trials. About the author. People who live far away from major research sites or can’t take off work can also benefit from study visits at local doctors’ offices or community clinics.

Vaccines 111

Vaccines FDA Hospitals 111

pharmaphorum

NOVEMBER 11, 2021

The LOGEX and IVM report is also able to show how much can be done using open-source data, although it does draw on some propriety IQVIA data. That contrasts to comparisons such as those commissioned by the European industry group, EFPIA , that rely on proprietary data from IQVIA. About the author.

Dosage 52

Dosage 52

pharmaphorum

DECEMBER 4, 2022

About the author. Katie currently leads offering development at IQVIA for the Human Data Science Cloud. As the tech industry continues to flourish, successful companies will take active steps to support women in their career goals, while providing them with female mentorship from above and upward mobility career opportunities.

104

104

pharmaphorum

JUNE 11, 2021

If even a major health tech company such as IQVIA, which participated in AstraZeneca’s COVID vaccine trials, can be targeted, forcing researchers to track their patients using pen and paper, what of smaller companies down the chain? About the author. Treat them as such.

Vaccines 111

Vaccines HIPAA Immunization 111

pharmaphorum

OCTOBER 6, 2021

More than 90,000 health-related mobile apps were released onto the market in 2020 alone, according to an IQVIA Institute report , that’s an average of 250-plus every day. About the author. We are living through a digital health revolution, and the pace of change has been accelerated by the COVID-19 pandemic.

Hospitals 98

Hospitals 98

European Pharmaceutical Review

JULY 20, 2022

Real-world data was gathered from IQVIA Medical Research Data (IMRD) electronic health records (eHR) databases for France, Germany and the UK to find out how many patients were using each drug during the 12 months before and after regulatory action. About the author. tetrazepam – a muscle relaxant. Real-world data and results.

Adverse Reactions 80

Adverse Reactions Hospitals Vaccines 80

pharmaphorum

JANUARY 27, 2021

Held in association with IQVIA , the discussion brought together clinical, data science, RWE and health data expertise. IQVIA has already helped establish innovative ways to overcome these obstacles. A unique health data ecosystem for improving patient care.

Patient Care 142

Patient Care Hospitals Chemotherapy Vaccines 142

pharmaphorum

OCTOBER 5, 2021

According to a recent study by IQVIA , there are 438 clinical studies with 933 digital biomarkers that measure patient status, and more than 20 regulatory approved digital therapeutics commercially available today. About the author. We need to support the transformation of the global care system for the health of our children.

Hospitals 130

Hospitals Documentation Pharmaceutical Companies Pharmaceutical Companies 130

pharmaphorum

SEPTEMBER 3, 2020

IQVIA has quantitatively tracked the impact of COVID on the way pharma engages with its customers using its ChannelDynamics audit of HCP/pharma engagement, specific primary research, as well as the IQVIA MIDAS and audits on Rx sales and patient visits and treatments. But that doesn’t mean we are completely flying blind.

Pharmaceutical Companies 84

Pharmaceutical Companies Pharmaceutical Companies 84

pharmaphorum

OCTOBER 26, 2022

Working with IQVIA, they found that the cost for 8.4 About the author. As a result, society and government bodies have not developed models and policies that adequately support the development of and access to rare disease drugs.”. million rare disease patients in the U.S. is approximately $2.2 trillion per year.

Patient Care 88

Patient Care FDA 88

pharmaphorum

JANUARY 16, 2023

Last year, IQVIA predicted that 2022 would be the crunch year for Alzheimer’s therapies: it is with a sense of déjà vu that the exact same prediction is contemplated for 2023. About the author. The hard problem: innovation for high prevalence, chronic diseases of ageing. She holds a degree in biochemistry from Oxford University.

FDA 94

FDA Pharmaceutical Companies Pharmaceutical Companies Compounding 94

pharmaphorum

JANUARY 5, 2021

In the first of a two part series, IQVIA’s Sarah Rickwood covers nine key trends and events that will affect the global healthcare and pharmaceutical industries in 2021. Throughout 2020, IQVIA data, both secondary and primary research pointed to often substantial share of non-COVID-19 patients receiving no, or suboptimal treatment.

Hospitals 105

Hospitals Vaccines Pharmaceutical Companies Pharmaceutical Companies 105

pharmaphorum

OCTOBER 20, 2020

Sarah Rickwood delves into IQVIA data to find out exactly how pharma’s HCP engagement has changed over COVID-19, and what the channel mix might look like after the pandemic. About the Author. The pandemic has triggered a change in how pharmaceutical companies are engaging with healthcare professionals. The answer was yes.

Pharmaceutical Companies 122

Pharmaceutical Companies Pharmaceutical Companies Documentation Communication 122

pharmaphorum

JUNE 29, 2022

COVID vaccines and treatments have created a substantial market over and above the existing Rx market- IQVIA estimates that the cumulative value of COVID vaccines could be between $185 and 295bn to 2026. About the author. Sarah Rickwood, VP, EMEA Thought Leadership and Marketing, IQVIA. Orphan drugs launch challenges.

HIV Treatment and Prevention Agents 59

HIV Treatment and Prevention Agents Vaccines Pharmaceutical Companies Pharmaceutical Companies 59

pharmaphorum

SEPTEMBER 30, 2022

The traceability of components is critical for authoring structured content correctly, especially when it comes to fulfilling compliance regulations. The largest barrier is the perception that all documents must first be broken down into components before using component-based authoring tools. About the author.

Documentation 52

Documentation Pharmaceutical Companies Pharmaceutical Companies 52

pharmaphorum

JANUARY 14, 2021

However, qualitative interviews conducted by IQVIA with HCPs in the top 5 European countries on their experience of engagement with pharma during 2020 show that doctors still valued interaction, including face to face interaction, with pharma and missed it when it was absent. About the author.

Pharmaceutical Companies 66

Pharmaceutical Companies Pharmaceutical Companies Labelling 66